# Oruka Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Oruka Therapeutics, Inc.).

## Overview

Oruka Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its pipeline centers on ORKA-001 and ORKA-002, with a third program, ORKA-003, aimed at an undisclosed pathway for inflammatory disease applications.

## Products & services

• ORKA-001: IL-23p19 monoclonal antibody for psoriasis
• ORKA-002: IL-17A/F monoclonal antibody for psoriasis and HS
• ORKA-003: undisclosed inflammatory disease program
• Preclinical and clinical development of antibody therapeutics
• Out-licensed development and commercialization rights

- **ORKA-001** (40%) — Clinical-stage antibody program targeting IL-23p19 for psoriasis.
- **ORKA-002** (40%) — Clinical-stage antibody program targeting IL-17A/F for psoriasis, HS, and related I&I diseases.
- **ORKA-003** (10%) — Earlier-stage undisclosed pathway program for inflammatory dermatology and I&I expansion.
- **Licensing and collaboration rights** (10%) — Exclusive worldwide rights to develop and commercialize licensed antibody programs.

- ORKA-001: IL-23p19 monoclonal antibody for psoriasis
- ORKA-002: IL-17A/F monoclonal antibody for psoriasis and HS
- ORKA-003: undisclosed inflammatory disease program
- Preclinical and clinical development of antibody therapeutics
- Out-licensed development and commercialization rights

## Customers

Oruka does not yet sell commercial products; its near-term counterparties are clinical trial sites, contract research organizations, contract manufacturers, and other development partners that support its pipeline. If approved, its eventual customers would be physicians, hospitals, and specialty pharmacies serving patients with psoriasis, hidradenitis suppurativa, psoriatic arthritis, and related inflammatory diseases.

- **Clinical development partners** (primary) — CROs, investigators, labs, and CMOs that execute studies and supply drug material.
- **Future dermatology and immunology prescribers** (primary) — Physicians treating psoriasis, HS, PsA, and other inflammatory conditions if products are approved.
- **Healthcare delivery channel** (secondary) — Hospitals, specialty pharmacies, and distributors that would handle commercial access.

- Clinical trial investigators and medical institutions running studies
- CROs and contract labs supporting preclinical and clinical work
- CMOs and other suppliers manufacturing antibody drug material
- Future prescribers treating psoriasis and related I&I diseases
- Specialty pharmacies and distributors if products are commercialized

## Geography

Oruka is headquartered in Menlo Park, California and operates as a U.S.-based development company. Its programs are intended for the United States and other key markets, and its clinical and regulatory work can extend into foreign jurisdictions through global trial and licensing activities.

- Headquartered in Menlo Park, California
- U.S. is the core operating and development base
- Clinical trials may involve sites outside the U.S.
- Commercial plans include the U.S. and other key markets
- Foreign regulatory regimes affect trial and approval execution

## Strategy

Oruka’s strategy is to focus on a small number of differentiated antibody programs in inflammatory dermatology, using validated biology and half-life extension to improve dosing convenience. It seeks to advance ORKA-001 and ORKA-002 through clinical development while preserving optionality for future commercialization or strategic collaboration.

- **Advance ORKA-001 and ORKA-002 through clinical development** (short-term) — Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
- **Differentiate through dosing and exposure profile** (medium-term) — Longer dosing intervals can improve adoption versus existing biologics.
- **Preserve commercialization and partnering optionality** (medium-term) — A flexible go-to-market model can maximize value if programs succeed.

- Focus on psoriasis and adjacent inflammatory dermatology markets
- Use validated targets to reduce scientific and clinical risk
- Engineer longer-acting antibodies to improve dosing convenience
- Advance ORKA-001 and ORKA-002 through clinical milestones
- Retain flexibility to commercialize or partner in key markets

## Risks

Oruka is a clinical-stage company with no approved products, so its value depends on successful trial outcomes, regulatory clearance, and eventual manufacturing scale-up. It also relies on third parties for research, manufacturing, and supply, while its licensed programs carry milestone and royalty obligations to Paragon.

- **Clinical development failure** [critical] — Pipeline value depends on positive efficacy and safety data in psoriasis and related indications.
- **Regulatory approval risk** [high] — Even successful trials may not translate into approval or favorable labeling.
- **Third-party manufacturing and supply dependence** [high] — The company does not own manufacturing facilities and relies on CMOs and suppliers.
- **IP and license dependence** [high] — Core programs are licensed from Paragon and carry milestone and royalty obligations.
- **Financing and dilution risk** [high] — As a pre-revenue biotech, continued operations depend on external capital.

- Clinical failure risk across early-stage antibody programs
- Regulatory risk for first-in-class or differentiated biologics
- Dependence on CROs, CMOs, and other third parties
- Intellectual property and licensing dependence on Paragon
- No commercial revenue and continued funding needs

## Accounting

The main accounting judgments are tied to research and development expense recognition, milestone obligations, and the valuation of acquired or licensed rights. As a pre-revenue biotech, the company also faces judgment around contingent liabilities, lease commitments, and any future fair-value measurements tied to financing or acquisition accounting.

- **Research and development expense recognition** — Clinical milestone timing can create volatility in reported operating expenses.
- **License milestone and royalty obligations** — These obligations affect accrued liabilities and future cash outflows.
- **Reverse merger and transaction accounting** — Purchase accounting, equity presentation, and transaction costs can materially affect reported results.
- **Lease commitments** — Lease liabilities and right-of-use assets affect the balance sheet and cash flow presentation.

- R&D expense timing for clinical milestones and third-party services
- License milestone and royalty accruals to Paragon
- Acquisition accounting from the reverse merger and related transaction costs
- Lease accounting for headquarters and office commitments
- Fair value judgments for warrants, preferred stock, and financing instruments

---

*Last updated: 2026-04-29T04:44:35.237651+00:00*